

FIG. 1

DWVIPPINLPENSRGPFPPQELVRI <sup>4.8G</sup> SDRDKNLSRYSVTGPGADQPPTGIFIINP	mNC
DWVIPPISCPENEKGEFPKNLVQIKSNRDKETKVFYSITGQGADKPPVGVFIER	mEC
BV9 Cad5	
DWIWNQMHIDEKNTESPHHVGGIKSSVSRK-NAKYLLKGEYVGK----VERVDA	hVEC
<u>DWIWNQMHIDEKNE</u> SLPHYV- <u>KDQSNVNRQ-NAKYVLQGEFAGK</u> ----IFGVDA	mVEC
Peptide 1	Peptide 2
Peptide 3	Peptide 4
ISGQLSVTKPLDRELIA <sup>4.8G</sup> RHLRAH <sup>4.8G</sup> AVDIN-GNQVENPIDIVINVIDMNDNRPEF	mNC
ETGWLKVTPQLDREAIAKYILYSH <sup>4.8G</sup> AVSSN-GEAVEDPMEIVITVTDQNDNRPEF	mEC
<b>ETG</b> DVFAIERLDRENISEYHLTAVIVDKDGTGENLETPSSFTIKVHDVNDNWPVE	hVEC
NTGNVLA <sup>4.8G</sup> YERLDREKVSEYFLTALIVDKNTNKNLEQPSSTVVKVHDINDNWPVF	MVEC

FIG. 2




FIG. 3




FIG. 4

**Effect of anti-VE-cadherin mAb 19E6 on  
b-FGF-induced neovascularization in  
mouse corneal micropocket assay**



Rat IgG1



19E6

FIG 5A




FIG. 5B




FIG. 6




FIG. 7






FIG. 8

**DWIWNQMHI DEEKNESLPHYVKDQSNVNRQNAKYVLQGEFAGKIFGVDAN**  
**E4B9** **19E6, 10G4 (Cad5)**

TGNVLAYERLDREKVSEYFLTALIVDKNTNKNLEQPSSFTVKVHDINDNWPVF

Murine ECD1

FIG. 9